Summit Therapeutics plc Award Of Restricted Stock Units
14 1월 2019 - 9:00PM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit Therapeutics" or the "Company")
Award of Restricted Stock Units
Oxford, UK, and Cambridge, MA, US, 14 January 2019 - Summit Therapeutics
(AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces
a grant of restricted stock units ('RSUs') was made to the Non-Executive
Directors on 11 January 2019. This grant is made according to the
Company's 2017 Remuneration Policy and represents the annual grant of
RSUs to the Company's Non-Executive Directors for the calendar year
2019. Details of the RSU grant are summarised below.
The Company also announces that its Non-Executive Chairman, Dr Frank
Armstrong, has surrendered 37,500 share options. The surrendered share
options were awarded in July 2014 and vested in March 2017. The decision
to surrender is part of the Company's objective of meeting best UK
corporate governance practice that favours non-performance remuneration
such as RSUs. As a result of this surrender, none of the Non-Executive
Directors now hold any share options, with any outstanding awards having
been surrendered during the current financial year.
Details of the Award of Restricted Stock Units
Director Position RSU's Awarded Total RSUs Held
-------------------- ----------------------- ------------- ---------------
Frank Armstrong Non-Executive Chairman 288,461 325,046
-------------------- ----------------------- ------------- ---------------
Leopoldo Zambeletti Non-Executive Director 134,615 151,688
-------------------- ----------------------- ------------- ---------------
Valerie Andrews Non-Executive Director 134,615 151,688
-------------------- ----------------------- ------------- ---------------
Dave Wurzer Non-Executive Director 134,615 151,688
-------------------- ----------------------- ------------- ---------------
Each RSU entitles the holder to subscribe for an Ordinary Share at a
subscription price of one penny per Ordinary Share. The RSUs have a
vesting period of one year and no performance conditions. The RSUs
granted will vest on 11 January 2020.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014 (MAR).
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens
and are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office) Tel: +44 (/0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / mailto:summit@consilium-comms.
com
summit@consilium-comms.com
------------------------------
Lindsey Neville
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
Details of the person discharging managerial responsibilities/person
1 closely associated
--- -----------------------------------------------------------------------------
a) Name Dr Frank Armstrong
--- ----------------------------- ----------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position / status Non-Executive Chairman
--- ----------------------------- ----------------------------------------------
Initial notification /
b) Amendment Initial notification
--- ----------------------------- ----------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Summit Therapeutics plc
--- ----------------------------- ----------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
--- ----------------------------- ----------------------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
--- -----------------------------------------------------------------------------
Description of the financial
instrument, type of
instrument Ordinary shares of 1 penny each
---
a) Identification code GB00BN40HZ01
--- ----------------------------- ----------------------------------------------
b) Nature of the transactions Grant of restricted stock units
--- ----------------------------- ----------------------------------------------
Price(s) Volume(s)
--- ----------------------------- ------------------------------ -----------
1 penny per share (subscription price) 288,461
---------------------------------------------------------------- -----------
c) Price(s) and volume(s)
--- -------------------------------------------------------------- -------------
Aggregated information
- Aggregated volume N/A
d) - Price
--- -------------------------------------------------------------- -------------
e) Date of the transaction 11 January 2019
--- ----------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--- ----------------------------- ----------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
--- -----------------------------------------------------------------------------
a) Name Leopoldo Zambeletti
--- ----------------------------- ----------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position / status Non-Executive Director
--- ----------------------------- ----------------------------------------------
Initial notification /
b) Amendment Initial notification
--- ----------------------------- ----------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Summit Therapeutics plc
--- ----------------------------- ----------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
--- ----------------------------- ----------------------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
--- -----------------------------------------------------------------------------
Description of the financial
instrument, type of
instrument Ordinary shares of 1 penny each
---
a) Identification code GB00BN40HZ01
--- ----------------------------- ----------------------------------------------
b) Nature of the transactions Grant of restricted stock units
--- ----------------------------- ----------------------------------------------
Price(s) Volume(s)
--- ----------------------------- ------------------------------ -----------
1 penny per share (subscription price) 134,615
---------------------------------------------------------------- -----------
c) Price(s) and volume(s)
--- -------------------------------------------------------------- -------------
Aggregated information
- Aggregated volume N/A
d) - Price
--- -------------------------------------------------------------- -------------
e) Date of the transaction 11 January 2019
--- ----------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--- ----------------------------- ----------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
--- -----------------------------------------------------------------------------
a) Name Valerie Andrews
--- ----------------------------- ----------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position / status Non-Executive Director
--- ----------------------------- ----------------------------------------------
Initial notification /
b) Amendment Initial notification
--- ----------------------------- ----------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Summit Therapeutics plc
--- ----------------------------- ----------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
--- ----------------------------- ----------------------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
--- -----------------------------------------------------------------------------
Description of the financial
instrument, type of
instrument Ordinary shares of 1 penny each
---
a) Identification code GB00BN40HZ01
--- ----------------------------- ----------------------------------------------
b) Nature of the transactions Grant of restricted stock units
--- ----------------------------- ----------------------------------------------
Price(s) Volume(s)
--- ----------------------------- ------------------------------ -----------
1 penny per share (subscription price) 134,615
---------------------------------------------------------------- -----------
c) Price(s) and volume(s)
--- -------------------------------------------------------------- -------------
Aggregated information
- Aggregated volume N/A
d) - Price
--- -------------------------------------------------------------- -------------
e) Date of the transaction 11 January 2019
--- ----------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--- ----------------------------- ----------------------------------------------
Details of the person discharging managerial responsibilities/person
1 closely associated
--- -----------------------------------------------------------------------------
a) Name Dave Wurzer
--- ----------------------------- ----------------------------------------------
2 Reason for the notification
--- -----------------------------------------------------------------------------
a) Position / status Non-Executive Director
--- ----------------------------- ----------------------------------------------
Initial notification /
b) Amendment Initial notification
--- ----------------------------- ----------------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
--- -----------------------------------------------------------------------------
a) Name Summit Therapeutics plc
--- ----------------------------- ----------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
--- ----------------------------- ----------------------------------------------
Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
4 where transactions have been conducted
--- -----------------------------------------------------------------------------
Description of the financial
instrument, type of
instrument Ordinary shares of 1 penny each
---
a) Identification code GB00BN40HZ01
--- ----------------------------- ----------------------------------------------
b) Nature of the transactions Grant of restricted stock units
--- ----------------------------- ----------------------------------------------
Price(s) Volume(s)
--- ----------------------------- ------------------------------ -----------
1 penny per share (subscription price) 134,615
---------------------------------------------------------------- -----------
c) Price(s) and volume(s)
--- -------------------------------------------------------------- -------------
Aggregated information
- Aggregated volume N/A
d) - Price
--- -------------------------------------------------------------- -------------
e) Date of the transaction 11 January 2019
--- ----------------------------- ----------------------------------------------
f) Place of the transaction Outside a trading venue
--- ----------------------------- ----------------------------------------------
-END-
(END) Dow Jones Newswires
January 14, 2019 07:00 ET (12:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Summit Therapeutics (LSE:SUMM)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
